The Global Rheumatoid Arthritis Market Forecasts to 2012

Table of Contents

1. Executive Summary

• 1.1 Aims of the Report
• 1.2 Summary and Contents

2. Immunity

• 2.1 Innate and Acquired Immune Systems
  • 2.1.1 Innate Immunity
  • 2.1.2 Acquired Immunity
• 2.2 Autoimmune Disease
  • 2.2.1 Antigens
  • 2.2.2 Autoantibodies
  • 2.2.3 Inflammation and Central Matrix Destruction
• 2.3 The Regulators of Inflammation
  • 2.3.1 Cytokine Storms
  • 2.3.2 Chemoattractant Chemokines
• 2.4 Spectrum of Autoimmune Disease
  • 2.4.1 Organ Specific AI Disease
  • 2.4.2 Non Organ Specific AI Disease

3. The Anti-inflammatory Market

• 3.1 Prescription Anti-inflammatory Drugs- Significant Economic Impact
• 3.2 World Arthritis market
• 3.3 The Anti-arthritis Market by Country
  • 3.3.1 North America
  • 3.3.2 Europe
  • 3.3.2 Asia by Country
  • 3.3.3 India
  • 3.3.4 Latin America by Country
• 3.3 Anti-inflammatory Drugs have Multiple Indications
• 3.4 The Key Players
• 3.5 Growth of the Immunomodulator Market
• 3.6 Diseases with Biggest Impact on the Pharmaceutical Market

4. Rheumatoid Arthritis (RA)

• 4.1 What is RA?
• 4.2 Aetiology of RA
  • 4.2.1 Genetic Predisposition
  • 4.2.2 Infectious Agents
  • 4.2.3 Rheumatoid Factor (RF)
  • 4.2.4 Pro-inflammatory Chemokines and Cytokines
  • 4.2.5 Smoking
• 4.3 Diagnosis, Differential Diagnosis , Biomarkers and Theranostics
  • 4.3.1 Diagnosis
  • 4.3.2 Differential Diagnosis
  • 4.3.3 Biomarkers
  • 4.3.4 Theranostics/Therapeutic Diagnostics in RA
• 4.4 Symptoms and Prognosis of RA
• 4.5 World Incidence, Prevalence and Impact of RA
  • 4.5.1 World Incidence and Prevalence of RA
  • 4.5.2 Impact of RA
  • 4.5.3 Time Trends in RA Up or Down?

5. Treatment of RA

• 5.1 NSAIDs
• 5.2 Glucocorticoids and Bridge Therapy
• 5.3 DMARDS
  • 5.3.1 Methotrexate
  • 5.3.2 Hydroxychloroquine
  • 5.3.3 Other DMARDs
• 5.4 Biological DMARDs
  • 5.4.1 TNF-? Antagonists
  • 5.4.2 Kineret (anakinra) Therapy
  • 5.4.3 MabThera/ Rituxan (Rituximab) Therapy
  • 5.4.4 Orencia (abatacept) Therapy
  • 5.4.6 Hyaluronic Acid Supplements and Osteoarthritis

6. Juvenile Arthritis a Special Market Area

• 6.1 Nomenclature and Definitions
• 6.2 Diagnosis
• 6.3 Prevalence
• 6.4 Symptoms and Signs
• 6.5 Treatment

7. Global Market Forecast

• 7.1 Increased Revenue Predicted for Global Arthritis Market
  • 7.1.1 Corticosteroids
  • 7.1.2 Methotrexate
  • 7.1.3 Other Anti-rheumatics
  • 7.1.4 Leading Brand Treatments for RA during 2006
• 7.2 Leading TNF-? Biologicals
  • 7.2.1 Enbrel
  • 7.2.2 Remicade
  • 7.2.3. Humira
  • 7.2.4 Conclusions
• 7.3 New RA Biologicals - Actemra, Kineret, Orencia and MabThera
  • 7.3.1 Actemra
  • 7.3.2 Orencia
  • 7.3.3. MabThera
• 7.4 NSAIDs- The COX Inhibitors (coxibs)
  • 7.4.1 The COX-2 Inhibitor Market during 2005-2006
  • 7.4.2 COX Inhibitor Market 2007-2012
  • 7.4.3 Celebrex (Celecoxib, Pfizer)
  • 7.4.4 Mobic (Meloxicam, Boehringer Ingelheim)
  • 7.4.5 Voltaren (Diclofenac, Novartis)
  • 7.4.6 Arthrotec (Diclofenac/Misoprostol, Pfizer)
  • 7.4.7 Arcoxia (Etoricoxib, Merck & Co)
  • 7.4.8 Lorcam (Lornoxicam, Taisho Pharmaceutical)
  • 7.4.9 Conclusions on the Future of COX-2 Inhibitor Market
• 7.5 Hyaluronic Acid Viscosupplementation
  • 7.5.1 Hyaluronic Supplements, 2005-2006
  • 7.5.2 Suvenyl 2007-20012
  • 7.5.3 Worldwide Revenues for Synvisc 2007-2012

8 SWOT Analyses

• 8.1 NSAIDs- Coxibs
• 8.2 Coxib Strengths
  • 8.2.1. Oral Formulations
  • 8.2.2 Fast Acting
  • 8.2.3 Broad Spectrum
  • 8.2.4 Inexpensive
• 8.3 Coxib Weaknesses
  • 8.3.1 Adverse Side Effect Profile
  • 8.3.2 Broad Spectrum No Underlying DMARD Activity with Daily Regimen
  • 8.3.3 Potential for Dependency
  • 8.3.4 Patent Expiry
• 8.4 Coxib Opportunities
  • 8.4.1 Combination Products
  • 8.4.2 New Drug Development
• 8.5 Coxib Threats
  • 8.5.1 Biological Competition
  • 8.5.2 New Coxibs?
• 8.6 The Biologicals
• 8.7 Strengths of Biologicals
  • 8.7.1 Specific, Effective DMARDs
  • 8.7.2 Favourable Patent Issues
• 8.8. Weaknesses of Biologicals
  • 8.8.1 Side Effects
  • 8.8.2 Expense
  • 8.8.3 Parenteral Route of Administration
• 8.9 Opportunities for Biologicals
  • 8.9.1 Multiple Target Pathways - Discovery Channels
  • 8.9.2 Novel Formulations
• 8.10 Threats for Biologicals
  • 8.10.1 Competition from Other Biologicals
  • 8.10.2 Research and Development
  • 8.10.3 New Product Introductions
  • 8.10.4 Biosimilars
    • 8.10.4.1 History
    • 8.10.4.2 Geography
    • 8.10.4.3 US and Europe
    • 8.10.4.4 Conclusion

9. Pipeline

• 9.1 Products in Phase III Clinical Trial
• 9.2 New Products
  • 9.2.1 Apadenoson (Adenosine Therapeutics)
  • 9.2.2 Belatacept (BMS)
  • 9.2.3 Rituximab (Genentech)
  • 9.2.4 Ofatumumab (GSK, Genmab)
  • 9.2.5 Belimumab (Cambridge Antibody Technology)
  • 9.2.4 CPH82 (Reumacon, Meda)
  • 9.2.5 AMG 162 (Amgen)
  • 9.2.6 Golimumab (Schering-Plough)
  • 9.2.6 Icatibant (Aventis, Jerini)
  • 9.2.9 Coxib 406381 (GSK)
  • 9.2.10 Conclusion

10. Conclusion

List of Tables

• 2.1 Pro-inflammatory and Anti-inflammatory Cytokines
• 2.2 Spectrum of Autoimmune Disease
• 3.1 World Sales of Leading Prescription Anti-inflammatories in 2006
• 3.2 Leading Brands for the Treatment of Arthritis to Q3 2006
• 5.1 Leading Brand COX Inhibitors for the Treatment of RA Worldwide ($m)
• 5.2 World Sales of Leading Systemic Corticosteroids/Corticosteroid Combinations, 2005
• 5.3 Steroids Commonly in Use for Treatment of Arthritis in the UK
• 5.3 Non-Biological DMARDS Used to Treat RA
• 6.1 Different Classifications for Juvenile Arthritis
• 6.2 Existing and Potential Biological for Potential Use in Juvenile Arthritis
• 7.1 Enbrel World Revenues and Annual Growth Rate, 2007-2012
• 7.2 Remicade World Revenues and Annual Growth Rate, 2007-2012
• 7.3 Forecast for Humira World Revenues and Annual Growth Rate, 2007-2012
• 8.1 SWOT Analysis of the COX- Inhibitors
• 8.1 SWOT Analysis of the Biologicals
• 9.1 Anti-rheumatics in the Pipeline

List of Figures

• 3.1 Global Anti-arthritis Market
• 3.2 Global Anti-arthritis Market Share
• 3.3 Global Anti-arthritis Market by Drug Category
• 3.4 North American Arthritis Market
• 3.5 North American Arthritis Market by Drug Class
• 3.6 The European Arthritis Market by Country
• 3.7 European Arthritis Market by Drug Category
• 3.8 Asian Arthritis Market by Country
• 3.9 Latin American Arthritis Drug Market by Country
• 3.10 Market Shares of the 6 leading RA Drugs
• 4.1 Prevalence of Arthritis in Different Countries
• 7.1 Revenue from the Leading Brand Arthritis Treatments in 2006
• 7.2 Global Sales of TNF-? Biologicals for the Treatment of Arthritis 2005/2006
• 7.3 Forecast for the TNF-? Biological Market, 2007-2012
• 7.4 Forecast for Individual TNF-? Products, 2007-2012
• 7.5 Revenue Forecast for Enbrel, 2007-2012
• 7.6 Annual Growth Rate for Enbrel, 2007-2012
• 7.7 Revenue Forecast for Remicade, 2007-2012
• 7.8 Annual Growth Rate for Remicade, 2007-2012
• 7.9 Revenue Forecast for Humira, 2007-2012
• 7.10 Annual Growth Rate for Humira, 2007-2012
• 7.11 World Sales of COX-2 Inhibitors in 2005
• 7.12 World Sales of COX-2 Inhibitors in 2006
• 7.13 Global Sales of Leading COX Inhibitors 2005/2006
• 7.14 Worldwide COX 2 Inhibitor Market 2007-2012
• 7.15 World Sales of Leading Brand COX Inhibitors, 2007-2012
• 7.16 Leading Brand COX Inhibitors, 2007-2012
• 7.17 Growth in the Sales of Viscosupplements during 2005-2006
• 7.18 Global Sales Forecast for Synvisc and Suvenyl 2007-2012

Organisations Listed

• Abbott
• Adenosine Therapeutics
• Amgen
• Axis Shield
• Biogen Idec
• Boehringer Ingelheim
• Bristol Myers Squib
• Cambridge Antibody Technology
• Chugai Pharmaceutical
• Conpharm
• Daiichi Sanyo
• Genentech
• Genesis Genmag
• Genzyme
• Glaxo Smith Kline
• Jerini
• Johnson & Johnson
• Lupin
• Meda
• Mylan
• Nippon Roussel
• Novartis
• Par Actavis
• Pharma
• Pharmacia
• Pfizer
• Roche
• Sanofi-Aventis
• Sanofi-Synthelabo
• Schering Plough
• Shire
• Sovereign
• Tanabe
• Teva
• UCB
• Upjohn
• Watson
• Wyeth